AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05834101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic streching
Description: The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
Study NCT05434104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal lactoferrin
Description: Lactoferrin vaginal pessaries to insert nightly for seven nights
Study NCT05434104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
Study NCT04684576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permobil Explorer Mini
Description: The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
Study NCT04684576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permobil Explorer Mini
Description: The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
Study NCT04684576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Ride-On Car
Description: Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
Study NCT04684576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Ride-On Car
Description: Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
Study NCT06290661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active electrostimulation
Description: Maintain the electrical stimulation state, and according to the patient's feeling to set the appropriate stimulation parameter range (pain relief and no obvious numbness and discomfort), the programme will be written into the patient's self-control remote control, by the patient according to their own pain situation for the independent control of the stimulation current.
Study NCT06290661 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo electrostimulation
Description: No actual electrostimulation
Study NCT05970185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
Study NCT05970185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
Study NCT05209360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial or Lateral Wedge
Description: A foam wedge that is placed inside the shoe under the CDO, that runs along the length of the foot. The tall side of the wedge will be placed on the medial (Medial Wedge) or lateral (Lateral Wedge) aspect of the shoe to preferentially load the medial or lateral side of the foot.
Study NCT05209360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis
Description: A device that consists of a proximal cuff that wraps around the leg just below the knee, a posterior strut that runs the length of the leg, and a semi-rigid footplate that goes under the length of the foot.
Study NCT05205616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonopet ultrasonic saw
Description: Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
Study NCT05205616 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reciprocating saw
Description: See above description
Study NCT06095947 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Description: A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
Study NCT05119517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative medicine pedal pump
Description: In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
Study NCT06262880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant derived phenolics
Description: Dietary supplement containing plant derived phenolics
Study NCT06262880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystaline cellulose (MCC)
Description: Placebo treatment: Microcrystaline cellulose
Study NCT06022744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX109
Description: LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
Study NCT06145802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT316
Description: Autologous Tumor Infiltrating Lymphocyte Injection
Study NCT04907513 — intervention group
Intervention type: OTHER
Intervention: Assessment of the Motivational State
Description: A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
Study NCT05205798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food consumption using plates with a diameter of 23 cm.
Description: In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
Study NCT05205798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Washout period
Description: No interventional food consumption for 1 week
Study NCT05205798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food consumption using plates with a diameter of 31 cm.
Description: In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
Study NCT05663346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis & Cancer digital educational intervention
Description: The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.
Study NCT05663346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard information regarding cannabis use in oncology
Description: Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
Study NCT06182098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1/2 maintenance fluids
Description: Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.
Study NCT06182098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 0.5mg/kg, with a maximum of 30mg
Study NCT06182098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: 0.5mg/kg, with a maximum of 30mg
Study NCT06182098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 0.5mg/kg, with a maximum of 25mg
Study NCT06182098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: 0.5mg/kg, with a maximum of 25mg
Study NCT04802382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: patients will receive the placebo treatment in addition to Standard of Care
Study NCT06182098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: 0.15mg/kg, with a maximum of 10mg
Study NCT06182098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prochlorperazine
Description: 0.15mg/kg, with a maximum of 10mg
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Confirm SARS-CoV-2 infection
Description: patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Study NCT06182098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bolus
Description: 20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Confirm SARS-CoV-2 infection
Description: patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Study NCT05454462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP Application KM-001
Description: KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
Study NCT04802382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: patients will undergo a physical examination on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Examination
Description: patients will undergo a physical examination on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: patient's vital signs will be measured on days 1-14 and day 28
Study NCT05454462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IMP Application KM-001
Description: KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chemistry
Description: patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Chemistry
Description: patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology
Description: patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hematology
Description: patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinalysis
Description: Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Urinalysis
Description: Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serelogy
Description: Patients will provide a blood sample for serelogy test at day -14 (screening visit)
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Serelogy
Description: Patients will provide a blood sample for serelogy test at day -14 (screening visit)
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 12-Lead ECG
Description: patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 12-Lead ECG
Description: patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pregnancy test
Description: Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood PK sampling
Description: PK test will be performed on day 1, 7, 28, 35 and on ET visit
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood PK sampling
Description: PK test will be performed on day 1, 7, 28, 35 and on ET visit
Study NCT05454462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: patients will undergo a physical examination on all the clinical visits
Study NCT05454462 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Examination
Description: patients will undergo a physical examination on all the clinical visits
Study NCT05454462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital signa
Description: patient's vital signs will be measured on all the clinical visits
Study NCT05454462 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vital signa
Description: patient's vital signs will be measured on all the clinical visits
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Investigator's Global Assessment
Description: patient's disease evaluations will be evaluated on all the clinical visits
Study NCT04802382 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vital Signs
Description: patient's vital signs will be measured on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology blood test
Description: patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hematology blood test
Description: patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemistry blood test
Description: patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Biochemistry blood test
Description: patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEWS score
Description: patient's NEWS score will be evaluated on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NEWS score
Description: patient's NEWS score will be evaluated on days 1-14 and day 28
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PK test
Description: PK test will be performed on day 1 only (only in Brazil sites)
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: PK test
Description: PK test will be performed on day 1 only (only in Brazil sites)
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test for inflammatory markers
Description: patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Investigator's Global Assessment
Description: patient's disease evaluations will be evaluated on all the clinical visits
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Itch Assessment via PP-NRSj
Description: patient's disease evaluations will be evaluated on all the clinical visits
Study NCT05454462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Itch Assessment via PP-NRSj
Description: patient's disease evaluations will be evaluated on all the clinical visits
Study NCT05454462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-diary data
Description: The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
Study NCT04814524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Wear Fitbit
Study NCT04814524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: blood test for inflammatory markers
Description: patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-dimer test
Description: patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
Study NCT06298591 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: co2 laser
Description: laser
Study NCT04802382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: D-dimer test
Description: patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
Study NCT04802382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAS scale
Description: patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
Study NCT04673422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Study NCT04673422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Study NCT06457880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG BLOCK
Description: Preoperative ultrasound guided PENG block (ropivacaine 0.5 % 20 mL)
Study NCT06457880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Preoperative ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL)
Study NCT06457880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obturator Nerve Block
Description: Preoperative ultrasound guided obturator nerve block (ropivacaine 0.5 % 5 mL)
Study NCT06266078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative PPE
Description: The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall
Study NCT06266078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional PPE
Description: The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
Study NCT05454462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-diary data
Description: The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
Study NCT05214885 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study